source
- Merck's dealmaker warns of increased M&A activity as Keytruda patent expiresMerck's chief M&A officer says the company expects a surge in deal flow as the patent for its flagship immunotherapy, Keytruda, approaches expiration. The leadership has been pursuing acquisitions…
- Merck to test experimental sac-TMT antibody-drug conjugate with Keytruda in lung cancer trialMerck announced it will start a clinical trial testing its experimental antibody-drug conjugate sac-TMT together with the immunotherapy Keytruda in patients with lung cancer. The study will assess…